Capital expenditure increased 197.9%
Capital expenditure changed +197.9% from the comparable as-filed period. The change ranks at the 50th percentile of 4 prior comparable changes.
Ranked by interpretable importance, issuer history, magnitude, and accounting profile. No directional recommendation.
Capital expenditure changed +197.9% from the comparable as-filed period. The change ranks at the 50th percentile of 4 prior comparable changes.
Cash & equivalents changed +20.5% from the comparable as-filed period.
Capex / revenue changed +231 basis points from the comparable as-filed period.
R&D / revenue changed -1352 basis points from the comparable as-filed period.
Free-cash-flow margin changed -2193 basis points from the comparable as-filed period.
Working capital / assets changed -282 basis points from the comparable as-filed period. The change ranks at the 0th percentile of 4 prior comparable changes.
Receivables / revenue changed -344 basis points from the comparable as-filed period.
Research & development changed +12.8% from the comparable as-filed period.
Stock-based compensation changed -13.9% from the comparable as-filed period.
Current liabilities changed -3.6% from the comparable as-filed period. The change ranks at the 25th percentile of 4 prior comparable changes.
Method Importance combines metric-family relevance, magnitude, issuer-history unusualness, persistence, and financial-statement significance. It is analytical prioritization, not a legal materiality conclusion or investment signal.